MA诱导方案与DA诱导方案对老年急性髓系白血病患者血清炎症因子及复发率的影响

目的:探讨米托蒽醌联合阿糖胞苷(MA方案)与柔红霉素联合阿糖胞苷(DA方案)对老年急性髄系白血病(AML)患者血清炎症因子及复发率的影响.方法:选取2015年1月～2018年1月期间深圳市人民医院收治的老年AML患者129例,根据治疗方案的不同将患者分为DA组(n=64,DA方案治疗)和MA组(n=65,MA方案治疗)...

The Effect of MA Induction and DA Induction on Inflammatory Factors and Recurrence Rate in Elderly Patients with Acute Myeloid Leukemia

Objective: To investigate the effect of mitoxantrone combined with cytarabine(MA) and daunorubicin combined with cytarabine(DA) on inflammatory factors and recurrence rate in elderly patients with acute myeloid leukemia(AML). Methods: 129 elderly AML patients who were admitted to Shenzhen People’s Hospital from January 2015 to January 2018 were selected, the patients were divided into DA group(n=64, DA scheme treatment) and MA group(n=65, MA scheme treatment) according to different treatment schemes, the curative effect, inflammatory factors, adverse reactions and recurrence rate of the two groups were compared. Results: The total clinical effective rate of MA group was higher than that of DA group after treatment(P<0.05). The levels of IFN-γ-inducible protein-10(IP-10), macrophage inflammatory protein-1α(MIP-1α) and soluble intercellular adhesion molecule-1(sICAM-1) were all decreased of the two groups after treatment, and the level of MA group was lower than that of DA group(P<0.05). The cumulative recurrence rate in patients with complete remission of group MA was lower than that of group DA(P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Compared with DA induction program, MA induction program can effectively improve the level of inflammatory factors and reduce the recurrence of elderly AML patients, and has better drug safety.